A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.

A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.

We developed and validated a two-gene signature that predicts prognosis in previously-untreated chronic lymphocytic leukemia (CLL) patients. Using a 65 sample training set, from a cohort of 131 patients, we identified the best clinical models to predict time-to-treatment (TTT) and overall survival (...

Full description

Bibliographic Details
Main Authors: Carmen D Schweighofer, Kevin R Coombes, Lynn L Barron, Lixia Diao, Rachel J Newman, Alessandra Ferrajoli, Susan O'Brien, William G Wierda, Rajyalakshmi Luthra, L Jeffrey Medeiros, Michael J Keating, Lynne V Abruzzo
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3237436?pdf=render

Internet

http://europepmc.org/articles/PMC3237436?pdf=render

Similar Items